• Bacterial infections

Kimyrsa Generic Name & Formulations

General Description

Oritavancin 1200mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains mannitol; preservative-free.

Pharmacological Class


How Supplied

Single-dose vial—1


Generic Availability


Kimyrsa Indications


Susceptible acute bacterial skin and skin structure infections (ABSSSI).

Kimyrsa Dosage and Administration


Give by IV infusion over 1hr. ≥18yrs: 1200mg as a single dose.


<18yrs: not established.

Kimyrsa Contraindications


Use of IV unfractionated heparin sodium for 120hrs (5 days) after oritavancin administration.

Kimyrsa Boxed Warnings

Not Applicable

Kimyrsa Warnings/Precautions


History of glycopeptide allergy. Discontinue immediately if acute hypersensitivity reaction occurs. Consider stopping or slowing infusion if infusion-related reactions occur. Evaluate if Clostridioides difficile-associated diarrhea is suspected or confirmed. Monitor for osteomyelitis; use alternative therapy if suspected or diagnosed. Severe hepatic or renal impairment: not studied. Pregnancy. Nursing mothers.

Kimyrsa Pharmacokinetics

See Literature

Kimyrsa Interactions


Increased risk of bleeding with concomitant warfarin; may prolong aPTT for up to 120hrs, PT/INR for up to 12hrs, and ACT for up to 24hrs; monitor for bleeding. Avoid concomitant with drugs that are predominantly metabolized by one of the affected CYP450 enzymes. May increase concentrations of CYP2C9/CYP2C19 substrates. May decrease concentrations of CYP3A4/CYP2D6 substrates. May interfere with coagulation tests; consider non-phospholipid dependent test (eg, Factor Xa assay) or alternative anticoagulant not requiring aPTT monitoring.

Kimyrsa Adverse Reactions

Adverse Reactions

Headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea; infusion-related reactions.

Kimyrsa Clinical Trials

See Literature

Kimyrsa Note

Not Applicable

Kimyrsa Patient Counseling

See Literature